Portal de Periódicos da CAPES

Pathological Outcomes Associated With the 17q Prostate Cancer Risk Variants

2009; Lippincott Williams & Wilkins; Volume: 181; Issue: 6 Linguagem: Inglês

10.1016/j.juro.2009.01.109

1527-3792

Brian T. Helfand, Stacy Loeb, Joshua J. Meeks, Angela J. Fought, Donghui Kan, William J. Catàlona,

Genetic factors in colorectal cancer

No AccessJournal of UrologyAdult Urology1 Jun 2009Pathological Outcomes Associated With the 17q Prostate Cancer Risk Variantsis accompanied byBone Morphogenetic Protein-10 Suppresses the Growth and Aggressiveness of Prostate Cancer Cells Through a Smad Independent Pathway Brian T. Helfand, Stacy Loeb, Joshua J. Meeks, Angela J. Fought, Donghui Kan, and William J. Catalona Brian T. HelfandBrian T. Helfand , Stacy LoebStacy Loeb , Joshua J. MeeksJoshua J. Meeks , Angela J. FoughtAngela J. Fought , Donghui KanDonghui Kan , and William J. CatalonaWilliam J. Catalona View All Author Informationhttps://doi.org/10.1016/j.juro.2009.01.109AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: Recent studies have identified 2 distinct genetic variants along chromosome 17, including allele T of single nucleotide polymorphism rs4430796 on 17q12 and allele G of single nucleotide polymorphism rs1859962 on 17q24, that have been linked to prostate cancer risk. Less is known about tumor pathological features in carriers of these variants. Materials and Methods: Genotypes for regions 17q12 and 17q24 were determined in 759 white men with prostate cancer and compared to those in 790 healthy control volunteers using logistic regression. In patients with prostate cancer the Fisher exact or Kruskal-Wallis test was used as appropriate to assess the relationship(s) between clinical and pathological characteristics with 17q carrier status. Results: The frequency of the 17q12 and 17q24 genetic variants was significantly higher in patients with prostate cancer compared to that in controls (OR 1.32, 1.15, respectively). Of patients with prostate cancer 83% and 77% were carriers of the 17q12 and 17q24 variants as well as 75% and 75% of controls, respectively. Carriers of 17q12 risk variants were significantly more likely to have high grade disease using an additive best fit genetic model. In addition, there were trends toward adverse pathological features associated with 17q12 independent of the best fit genetic model. Conclusions: Sequence variants along 17q12 and 17q24 were present in a significantly higher proportion of our prostate cancer cases than in our controls. Adverse pathological features, including higher Gleason grade and pathological stage, were more frequent in 17q12 carriers. Since these alleles may act in conjunction with variants on other chromosomes to influence prostate cancer risk, additional research is required to determine the cumulative associations of genetic risk variants with prognosis. References 1 : Multiple prostate cancer risk variants on 8q24. Nat Genet2007; 39: 579. Google Scholar 2 : Multiple regions within 8q24 independently affect risk for prostate cancer. Nat Genet2007; 39: 638. Google Scholar 3 : Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. Nat Genet2007; 39: 631. Google Scholar 4 : Admixture mapping identifies 8q24 as a prostate cancer risk locus in African-American men. Proc Natl Acad Sci U S A2006; 103: 14068. Google Scholar 5 : A common variant associated with prostate cancer in European and African populations. Nat Genet2006; 38: 652. Google Scholar 6 : Multiple loci identified in a genome-wide association study of prostate cancer. Nat Genet2008; 40: 310. Google Scholar 7 : Confirmation study of prostate cancer risk variants at 8q24 in African Americans identifies a novel risk locus. Genome Res2007; 17: 1717. Google Scholar 8 : Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes. Nat Genet2007; 39: 977. Google Scholar 9 : Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer. Nat Genet2008; 40: 281. Google Scholar 10 : Multiple newly identified loci associated with prostate cancer susceptibility. Nat Genet2008; 40: 316. Google Scholar 11 : Cumulative association of five genetic variants with prostate cancer. N Engl J Med2008; 358: 910. Google Scholar 12 : Association between sequence variants at 17q12 and 17q24.3 and prostate cancer risk in European and African Americans. Prostate2008; 68: 691. Google Scholar 13 : Chromosome 17q12 variants contribute to risk of early-onset prostate cancer. Cancer Res2008; 68: 6492. Google Scholar 14 : Multiple novel prostate cancer predisposition loci confirmed by an international study: the PRACTICAL Consortium. Cancer Epidemiol Biomarkers Prev2008; 17: 2052. Google Scholar 15 : Cumulative effect of five genetic variants on prostate cancer risk in multiple study populations. Prostate2008; 68: 1257. Google Scholar 16 : Tumor characteristics of carriers and noncarriers of the deCODE 8q24 prostate cancer susceptibility alleles. J Urol2008; 179: 2197. Link, Google Scholar 17 : 8q24 and prostate cancer: association with advanced disease and meta-analysis. Eur J Hum Genet2008; 16: 496. Google Scholar 18 : Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat Genet2007; 39: 645. Google Scholar 19 : Two common chromosome 8q24 variants are associated with increased risk for prostate cancer. Cancer Res2007; 67: 2944. Google Scholar 20 : Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med2004; 351: 125. Google Scholar 21 : Familial and genetic aspects of prostate cancer. AUA Update Series2003; 22. lesson 20. Google Scholar Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, and The James Buchanan Brady Urological Institute, The Johns Hopkins University (SL), Baltimore, Maryland© 2009 by American Urological AssociationFiguresReferencesRelatedDetailsCited byHelfand B, Fought A, Loeb S, Meeks J, Kan D and Catalona W (2010) Genetic Prostate Cancer Risk Assessment: Common Variants in 9 Genomic Regions are Associated With Cumulative RiskJournal of Urology, VOL. 184, NO. 2, (501-505), Online publication date: 1-Aug-2010.Related articlesJournal of Urology17 Apr 2009Bone Morphogenetic Protein-10 Suppresses the Growth and Aggressiveness of Prostate Cancer Cells Through a Smad Independent Pathway Volume 181Issue 6June 2009Page: 2502-2507 Advertisement Copyright & Permissions© 2009 by American Urological AssociationKeywordshumanchromosomespair 17prostateprostatic neoplasmsgene expressionriskMetricsAuthor Information Brian T. Helfand More articles by this author Stacy Loeb More articles by this author Joshua J. Meeks More articles by this author Angela J. Fought More articles by this author Donghui Kan More articles by this author William J. Catalona Financial interest and/or other relationship with Beckman Coulter and deCODE Genetics. More articles by this author Expand All Advertisement PDF downloadLoading ...